-
Gepotidacin: Mechanism of S. aureus Gyrase Action
2026-09-10
The reference study established how Gepotidacin (GSK2140944) inhibits Staphylococcus aureus gyrase through an unusual cleavage phenotype dominated by single-stranded DNA breaks rather than the double-stranded breaks associated with fluoroquinolones. By combining biochemical assays, competition experiments, and crystal structures, the work connected target engagement with a distinct binding site and provided a mechanistic foundation for antibacterial research on fluoroquinolone-resistant pathogens.
-
Busulfan Mechanism and Lineage Tracing
2026-09-09
Busulfan is a DNA alkylating agent used to model DNA damage, senescence, and germ-cell depletion. Evidence from dual-recombinase tracing shows that busulfan-induced ovarian injury did not produce labeled growing oocytes or metaphase II eggs in mice.
-
Aedes aegypti Xenobiotic Transport and Olsalazine
2026-09-09
Kennel and Rouhier investigate how Aedes aegypti mosquitoes clear injected xenobiotics by combining excretion measurements with qPCR analysis of six putative organic cation transporters. The study shows that chemical structure strongly affects excreted volume, excreted material composition, and mortality, whereas transporter transcript responses are comparatively limited.
-
VX-702: Designing Better p38α MAPK Assays
2026-09-08
VX-702 is a selective p38α MAPK inhibitor suited to mechanistic inflammation research. This article explains how to distinguish catalytic blockade from activation-loop dephosphorylation and translate that distinction into stronger cytokine, arthritis, platelet, and cardiac assays.
-
XYD113: Selective GSPT1 Degradation in MYC Cancers
2026-09-08
The reference study identifies XYD113 as a potent molecular glue degrader that selectively removes GSPT1 through a CRBN-dependent ubiquitin–proteasome mechanism. Its activity across MYC-overexpressing cancer models, favorable substrate selectivity, and oral xenograft efficacy support further investigation while leaving important questions about clinical translation and long-term safety.
-
Rosiglitazone Workflows for Adipose Browning
2026-09-07
Build more informative adipocyte and metabolic assays with Rosiglitazone, a tunable PPARγ perturbation rather than a standalone browning marker. This workflow pairs Brl-49653 with genetic SETD7 models, thermogenic readouts, and insulin-response measurements to separate adipogenesis from beige-fat function.
-
JC-1 Mitochondrial Membrane Potential Assay Guide
2026-09-05
Turn mitochondrial depolarization into a practical, ratiometric endpoint for apoptosis studies, drug screening, and mitochondrial function analysis. This workflow shows how to use CCCP controls, optimize staining, and extend findings from a hypoxia-activated cancer therapy study without mistaking ΔΨm loss for complete proof of apoptosis.
-
Dual Recombinase Tracing Finds No Postnatal Neo-Oogenesis
2026-09-05
Xie, Zhou, and Zheng combine Cre-loxP and Dre-rox lineage tracing to test whether postnatal mouse ovarian cells generate new oocytes. Across physiological aging and busulfan-induced ovarian injury, the study detected no labeled growing oocytes or MII eggs, providing strong in vivo evidence against postnatal neo-oogenesis in mice.
-
cgSHAPE-seq Maps SARS-CoV-2 RNA Degrader Binding
2026-09-04
The reference study introduces cgSHAPE-seq, a sequencing-based strategy that identifies where small molecules bind structured RNA, and applies it to the SARS-CoV-2 5′ untranslated region. Mapping a bulged guanosine in the SL5 four-way helix enabled construction of an RNase L-recruiting chimera that reduced viral RNA expression and inhibited live-virus replication in lung epithelial carcinoma cells.
-
Kanamycin Sulfate: Workflows, Selection & Troubleshooting
2026-09-04
Build more reliable bacterial selection workflows with a water-soluble antibiotic suited to plasmid maintenance, resistance profiling, and protein-synthesis assays. This guide also shows how selection-stage quality control can complement newer circular RNA purification strategies without confusing upstream antibiotic use with downstream RNA processing.
-
Rosiglitazone (Brl-49653) in PPARγ Assays
2026-09-03
Rosiglitazone (Brl-49653) provides a practical ligand-based way to interrogate PPARγ activation in adipogenesis, insulin sensitivity modulation, and PPARG variant rescue. This workflow combines transcriptional, protein-stability, mitochondrial, and metabolic readouts to distinguish genuine pathway rescue from nonspecific changes in cell health.
-
AZD6482 Workflows for PI3Kβ Mechanistic Studies
2026-09-02
AZD6482 is a selective PI3Kβ inhibitor for separating platelet, metabolic, and cell-state signaling effects without treating every phenotype as pan-PI3K suppression. This workflow combines formulation guidance, dose-matrix design, RNA-foci readouts, and troubleshooting for exploratory studies inspired by recent DM1 research.
-
D-Luciferin Potassium Salt for BLI Workflows
2026-09-02
D-Luciferin potassium salt supports repeatable firefly luciferase readouts for tumor cell tracking, reporter assays, and ATP-linked measurements. Its water solubility makes it practical for serial in vivo bioluminescence imaging and controlled in vitro assay optimization, including mechanistic hepatocellular carcinoma studies.
-
Sinapine Targets PLCβ3 EF Hands in Cardiovascular Disease
2026-09-02
The April 2024 Phytomedicine study identifies sinapine as a chemical probe that targets the PLCβ3 EF-hand region, including Asn-260, to disrupt Gαq–PLCβ3 signaling in aldosteronism and hypertension models. Its main innovation is a more axis-focused strategy than direct Gαq inhibition, offering a mechanistic framework for developing PLCβ3-directed cardiovascular interventions while clarifying how downstream calcium assays can complement, but not replace, upstream target validation.
-
Vasopressin Analogues: Mechanisms and Research Uses
2026-09-01
Glavaš and colleagues review how vasopressin structure, receptor pharmacology, and peptide engineering have produced analogues with distinct antidiuretic, vasoconstrictive, and clinical profiles. The article is especially useful as a framework for interpreting lypressin, desmopressin, and terlipressin in receptor studies, treatment of diabetes insipidus, and emerging antiviral research.